In March 2021, Kromnigon joined the AstraZeneca’s BioVentureHub. Immunofluorescence microscopy is an imaging technique that can help visualise many proteins or cells in a single tissue section. The rapid expansion of immunofluorescence imaging within drug and diagnostics development is driven by the need to more accurately map immune cell influx into diseased tissues, such as tumours. This makes it easier to screen patients to determine personalized treatment therapies and to evaluate clinical responses.
Henric Olsson, Head of Target Science, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D at AstraZeneca, says, “It’s great to have Kromnigon co-locating with us at our R&D Gothenburg site through the BioVentureHub. We are keen to learn more about their tools and reagents for staining, visualizing and localising multiple proteins in the same tissue section, which may enable simultaneous extraction of more data from fewer samples.”
Per Fogelstrand, CEO at Kromnigon, says, ”We are very excited to be part of the creative and collaborative life science community that is being catalysed in the BioVentureHub. We are eager to share our expertise in immunofluorescence microscopy with fellow scientists at AstraZeneca and in the other BioVentureHub companies, and to being inspired to expand the development of our company and or products.”
Magnus Björsne, CEO for AstraZeneca’s BioVentureHub, says, “Kromnigon will – literally – add even more colour to our vibrant BioVentureHub innovation environment. We’re looking forward to working with Per and the Kromnigon team to help them accelerate the growth of their imaging innovations and to facilitate mutually beneficial scientific interactions between Kromnigon and AstraZeneca/BioVentureHub company scientists.”